Gilead Sciences Stock Surges 87% in Volume, Ranks 52nd in Market Activity After FDA Approval of Twice-Yearly HIV Prevention Drug

On June 18, 2025, Gilead Sciences (GILD) closed at a trading volume of $1.137 billion, marking an 87.25% increase from the previous day and ranking 52nd in the day's stock market activity. The company's stock price remained stable.

Gilead Sciences received FDA approval for its twice-yearly injectable lenacapavir, marketed under the brand name Yeztugo, for HIV prevention. This approval marks the first time a twice-yearly PrEP option has been available, offering a significant convenience for patients. The medication has been shown to reduce the risk of HIV transmission by more than 99.9% in adults and adolescents.

This approval is a significant milestone for Gilead, as it provides a new option for HIV prevention that requires only two treatments per year. The company has been working towards ending HIV, and this approval brings them one step closer to achieving that goal. The medication is now available in the United States for adults and adolescents weighing at least 35kg.